ZKSCAN3 promotes bladder cancer cell proliferation, migration, and invasion

The expression status of ZKSCAN3, a zinc-finger transcription factor containing KRAB and SCAN domains, as well as its biological significance, in human bladder cancer remains largely unknown. In the current study, we aimed to determine the functional role of ZKSCAN3 in bladder cancer progression. Immunohistochemistry in tissue specimens detected ZKSCAN3 signals in 138 (93.2%) of 148 urothelial neoplasms, which was significantly higher than in non-neoplastic urothelial tissues [76 (84.4%) of 90; P=0.044]. Correspondingly, the levels of ZKSCAN3 gene were significantly elevated in bladder tumors, compared with those in adjacent normal-appearing bladder mucosae (P=0.008). In a validation set of tissue microarray, significantly higher ZKSCAN3 expression was observed in high-grade and/or muscle-invasive urothelial carcinomas than in low-grade and/or non-muscle-invasive tumors. Two bladder cancer cell lines, UMUC3 and 647V, were found to strongly express ZKSCAN3 protein/mRNA, whereas its expression in 5637 bladder cancer and SVHUC normal urothelium cell lines was very weak. ZKSCAN3 silencing via its short hairpin RNA (shRNA) in UMUC3 and 647V resulted in significant decreases in cell viability/colony formation, cell migration/invasion, and the expression of matrix metalloproteinase (MMP)-2/MMP-9 and oncogenes c-myc/FGFR3, as well as significant increases in apoptosis and the expression of tumor suppressor genes p53/PTEN. ZKSCAN3 overexpression in 5637 also induced cell growth and migration. In addition, ZKSCAN3-shRNA expression considerably retarded tumor formation as well as its subsequent growth in xenograft-bearing mice. These results suggest that ZKSCAN3 plays an important role in bladder cancer outgrowth. Thus, ZKSCAN3 inhibition has the potential of being a therapeutic approach for bladder cancer.

[1]  S. Inoue,et al.  Androgen receptor activity modulates responses to cisplatin treatment in bladder cancer , 2016, Oncotarget.

[2]  S. Bunimovich-Mendrazitsky,et al.  Key signaling pathways in the muscle‐invasive bladder carcinoma: Clinical markers for disease modeling and optimized treatment , 2016, International journal of cancer.

[3]  E. Zwarthoff,et al.  Targeted therapies in bladder cancer: an overview of in vivo research , 2015, Nature Reviews Urology.

[4]  S. Inoue,et al.  Silodosin inhibits the growth of bladder cancer cells and enhances the cytotoxic activity of cisplatin via ELK1 inactivation. , 2015, American journal of cancer research.

[5]  S. Inoue,et al.  Compound A Inhibits Bladder Cancer Growth Predominantly via Glucocorticoid Receptor Transrepression. , 2015, Molecular endocrinology.

[6]  G. Netto,et al.  ELK1 is up-regulated by androgen in bladder cancer cells and promotes tumor progression , 2015, Oncotarget.

[7]  A. Jemal,et al.  Global cancer statistics, 2012 , 2015, CA: a cancer journal for clinicians.

[8]  G. Netto,et al.  Cyclosporine A and tacrolimus inhibit bladder cancer growth through down-regulation of NFATc1 , 2015, Oncotarget.

[9]  G. Sobue,et al.  Transcriptional activation of TFEB/ZKSCAN3 target genes underlies enhanced autophagy in spinobulbar muscular atrophy. , 2014, Human molecular genetics.

[10]  A. Lupo,et al.  KRAB-Zinc Finger Proteins: A Repressor Family Displaying Multiple Biological Functions , 2013, Current genomics.

[11]  A. Kamat,et al.  ZKSCAN3 is a master transcriptional repressor of autophagy. , 2013, Molecular cell.

[12]  J. Carpten,et al.  Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides. , 2012, Blood.

[13]  R. Orlowski,et al.  The zinc finger transcription factor ZKSCAN3 promotes prostate cancer cell migration. , 2012, The international journal of biochemistry & cell biology.

[14]  E. Messing,et al.  Expression of androgen and oestrogen receptors and its prognostic significance in urothelial neoplasm of the urinary bladder , 2012, BJU international.

[15]  K A Baggerly,et al.  Evidence of a role for the novel zinc-finger transcription factor ZKSCAN3 in modulating Cyclin D2 expression in multiple myeloma , 2011, Oncogene.

[16]  C. Cordon-Cardo,et al.  Molecular pathways of urothelial development and bladder tumorigenesis. , 2010, Urologic oncology.

[17]  Douglas D Boyd,et al.  Unbiased Screening for Transcriptional Targets of ZKSCAN3 Identifies Integrin β4 and Vascular Endothelial Growth Factor as Downstream Targets* , 2008, Journal of Biological Chemistry.

[18]  Douglas D Boyd,et al.  The previously undescribed ZKSCAN3 (ZNF306) is a novel "driver" of colorectal cancer progression. , 2008, Cancer research.

[19]  E. Messing,et al.  Promotion of bladder cancer development and progression by androgen receptor signals. , 2007, Journal of the National Cancer Institute.

[20]  J. Squire,et al.  Chromosome 6p amplification and cancer progression , 2006, Journal of Clinical Pathology.

[21]  Peter A. Jones,et al.  Mechanisms of Disease: genetic and epigenetic alterations that drive bladder cancer , 2005, Nature Clinical Practice Urology.

[22]  A. Evans,et al.  Defining a 0.5-mb region of genomic gain on chromosome 6p22 in bladder cancer by quantitative-multiplex polymerase chain reaction. , 2004, The American journal of pathology.

[23]  Raul Urrutia,et al.  KRAB-containing zinc-finger repressor proteins , 2003, Genome Biology.

[24]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.